OrchidBox's smart terrarium fits on your desktop. Courtesy OrchidBox

A Dallas startup has invented a smart terrarium with minimal maintenance designed to keep your plants alive. Called OrchidBox, it handles everything from easy succulents to hard-to-grow plants like the Venus flytrap.

The technology senses when the plant needs water and syncs with the sun for proper lighting.

Founder Nathan Hollis, a 26-year-old Dallas native, used his background in computer science and his love of plants to create an acrylic box equipped with LED lighting and a watering system.

The box measures 4x4x7 inches — small enough to fit on your work desk or bedside table. You can grow any plant that fits inside the box. An app allows you to select a pre-designed environment for your plant, and you can set a schedule for how much light and water it needs.

Hollis has a huge plant collection at home, some of which he has owned for seven years.

"It's sad, I don't think young people understand just how diverse our wildlife is, and we are losing more and more plant species every day," he says.

The name OrchidBox was selected to educate people about plant varieties and endangered species.

"While most people think of the stereotypical store-bought orchids, there are actually 50,000 species of orchids, some that are very, very bizarre," he says. "Most people don't know that, and some don't even know what an orchid is, so we wanted to take the opportunity to teach people."

The mini terrarium concept has been three years in the making. When he was in college, Hollis utilized his programming and mechanical engineering education to make climate-controlled devices that were larger, before sizing down his design to something that could adorn people's tabletops.

The company has competitors, such as Biopod Smart Microhabitat and EcoQube Air, but OrchidBox is the only company with a patent, said Taylor Mason, whose company It Crowd Marketing is helping Hollis with the media buzz.

Hollis had a full-time job but quit in February to focus exclusively on this venture. The product is available for pre-order which you can do here.

---

This story originally appeared on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.